![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://pharmaphorum.com/news/gsk-side-lines-covid-drug-otilimab-to-focus-on-xevudy/
https://www.clinicaltrialsarena.com/news/gsk-amend-covid-19-antibody-study/
https://health.economictimes.indiatimes.com/news/pharma/anti-inflammatory-and-cancer-drugs-tested-in-uk-as-possible-covid-19-therapy/76303703
https://www.clinicaltrialsarena.com/news/hydroxychloroquine-study-covid-19-data/
https://www.reuters.com/article/us-health-coronavirus-gsk-otilimab/gsk-to-test-experimental-drug-to-treat-pneumonia-from-covid-19-idUSKBN22J22L
http://www.pharmatimes.com/news/gsk_launches_phiii_programme_for_otilimab_in_ra_1293223